Setmelanotide

• CAT Number: I009449
• CAS Number: 920014-72-8
• Molecular Formula: C49H68N18O9S2
• Molecular Weight: 1117.32
• Purity: 95%
• Synonyms: RM-493; BIM-22493; IRC-022493; Setmelanotide.;(4R,7S,10S,13R,16S,19R,22R)-16-((1H-imidazol-5-yl)methyl)-7-((1H-indol-3-yl)methyl)-22-((S)-2-acetamido-5-guanidinopentanamido)-13-benzyl-10-(3-g
• Target: Agonist of the MC4 receptor
• Target Protein: P32245
• Solubility: Soluble in DMSO, not in water
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IUPAC Name: (4R,7S,10S,13R,16S,19R,22R)-22-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-13-benzyl-10-[3-(diaminomethylideneamino)propyl]-16-(1H-imidazol-5-ylmethyl)-7-(1H-indol-3-ylmethyl)-19-methyl-6,9,12,15,18,21-hexaoxo-1,2-dithia-5,8,11,14,17,20-hexazacyclotricosane-4-carboxamide
• InChI: InChI=1S/C49H68N18O9S2/c1-26-41(70)63-37(20-30-22-55-25-59-30)46(75)64-35(18-28-10-4-3-5-11-28)44(73)62-34(15-9-17-57-49(53)54)43(72)65-36(19-29-21-58-32-13-7-6-12-31(29)32)45(74)66-38(40(50)69)23-77-78-24-39(47(76)60-26)67-42(71)33(61-27(2)68)14-8-16-56-48(51)52/h3-7,10-13,21-22,25-26,33-39,58H,8-9,14-20,23-24H2,1-2H3,(H2,50,69)(H,55,59)(H,60,76)(H,61,68)(H,62,73)(H,63,70)(H,64,75)(H,65,72)(H,66,74)(H,67,71)(H4,51,52,56)(H4,53,54,57)/t26-,33+,34+,35-,36+,37+,38+,39+/m1/s1
• InChIKey: HDHDTKMUACZDAA-PHNIDTBTSA-N
• SMILES: C[C@@H]1C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N)CC2=CNC3=CC=CC=C32)CCCN=C(N)N)CC4=CC=CC=C4)CC5=CN=CN5

Setmelanotide（Cat No.:I009449）is a first-in-class melanocortin-4 receptor (MC4R) agonist used for the treatment of rare genetic disorders of obesity, such as proopiomelanocortin (POMC) deficiency and leptin receptor (LEPR) deficiency. By activating the MC4R pathway, Setmelanotide helps regulate hunger and energy expenditure, addressing the underlying cause of excessive hunger and obesity in these patients. Its targeted mechanism offers a novel therapeutic approach, leading to significant weight loss and improved metabolic outcomes. Setmelanotide provides a vital treatment option for individuals with genetic obesity syndromes that are resistant to conventional therapies.